How'd you fix Pear Therapeutics' revenue issues in 2026?

Pear needed to abandon the prescription-digital-therapeutics-as-standalone-drug model and pivot to embedded distribution (CVS-style PBM billing, employer bundles, health system partnerships) while narrowing focus to ONE indication with payer contracts locked before FDA filing. The $1.6B SPAC collapse happened because Pear chased prescriber adoption solo—commercializing like a pharma company without payer relationships baked in.

In a 2026 turnaround, a restructured Pear would need to: (1) choose reSET or reSET-O, not both; (2) sign three health plans to ironclad reimbursement agreements *before* launch; (3) plug into existing PBM infrastructure (like Big Health–CVS); (4) bundle with mental health or substance-use clinical delivery (telehealth, DSA integration); (5) prove $X cost savings per member in claims data.

What's Actually Broken

The Core Problem: Payer Hesitation at Scale

Pear's 2021–2022 playbook treated DTx like a pharma drug. They achieved FDA clearance (reSET in 2017, reSET-O in 2018, Somryst in 2020) but ignored that payers—not prescribers—control reimbursement. Pear CEO Corey McCann admitted on record: "Commercial payers are laggards," "Commercial payers can and will deny care." By 2021, Pear hit $110M annual expenses but only $4.2M revenue.

Revenue concentration around three payers with misaligned contracts amplified the crash. When those relationships fractured, Pear had no fallback distribution.

Payer Reimbursement Barriers (2023–2025)

1. Coverage Uncertainty: Payers waited for clinical evidence, outcome metrics, and standardized billing codes. Pear had FDA clearance but not payer *faith*. MassHealth eventually covered reSET/reSET-O, and CMS added a HCPCS code (prescription digital behavioral therapy) in 2021—but adoption remained glacial. As of 2024, 22 pharmacists and insurance representatives told researchers they were still waiting for clearer evidence or reimbursement pathways.

1. Billing Friction: The buy-and-bill model (provider pays upfront, submits claim, waits for reimbursement) is "not common practice" for mental health clinicians. Therapists, counselors, and addiction specialists expect insurance to handle payment; they won't float $500 per patient waiting 45 days for reimbursement.

1. Commoditization Risk: Once CMS and payers accepted the concept, DTx became a commodity. Akili (EndeavorRx for ADHD), Click Therapeutics, and Big Health (Sleepio, Daylight) all chased the same payers. Without proprietary IP or clinical differentiation, Pear couldn't defend pricing.

1. Integration Gaps: Pear was a pill-replacement play but had no native relationship with pharmacies, employers, or health systems. Big Health solved this by embedding with CVS PBM and billing like a drug. Welldoc solved it via employer direct contracts and health plan partnerships. Pear tried neither.

Competitive Benchmarks

• Akili Interactive (EndeavorRx): Acquired by Virtual Therapeutics (2024). Payer partnerships with UnitedHealth, Cigna. High-friction prescriber model; now absorbed into larger ecosystem.
• Big Health (Sleepio, Daylight): CVS Pharmacy PBM integration = pharmacy-counter billing. Partnerships with Evernorth, NHS, Macmillan. $75M+ funding 2025. Business model: payers first, prescribers second.
• Click Therapeutics: Acquired Pear's reSET/reSET-O IP in bankruptcy auction. Lower profile; embedded into pharma partnerships (Eli Lilly, etc.).
• Welldoc (BlueStar for diabetes): Direct-to-employer + health plan contracts. Proven $3,252/patient annual savings in claims data. Value-based pricing.
• Headspace Health (Ginger for mental health): Employer-facing subscription + clinical delivery. Moved away from prescription-only.

The 2026 Fix Playbook

1. Narrow the Portfolio to One Indication

Pear tried reSET, reSET-O, and Somryst simultaneously—three different markets, three times the sales friction. A 2026 restart picks one: probably reSET for substance use disorder (SUD), because addiction treatment is underfunded, has high provider demand, and aligns with telehealth/DSA expansion.

2. Lock Payer Contracts Before Filing or Launch

Sign UnitedHealth, Cigna, and Anthem to pilot reimbursement agreements *before* running prescriber sales. Structure as outcomes-based: "Pay $X per patient if compliance reaches Y% and no relapse within 30 days." Risk-sharing signals conviction.

3. Embed in PBM Infrastructure (Big Health + CVS Model)

Partner with CVS Health or other major PBM to bill through pharmacy, not provider manual claims. This means:

• Patient gets DTx prescription at pharmacy counter (printed card or digital code)
• Compliance tracked in PBM data backbone (no billing friction)
• Reimbursement automatic, triggered by claim adjudication
• Zero provider upfront cost

4. Bundle DTx + Clinical Delivery

DTx alone doesn't close addiction treatment gaps; humans do. Pear 2026 partners with DSA (Digital Service Agency) or teletherapy network:

• Addiction specialist provides intake, treatment plan, medication if needed (buprenorphine, naltrexone)
• ReSET digital module handles daily check-ins, cognitive behavioral therapy, accountability
• Prescriber bill covers both (DTx + counselor time); payer sees integrated outcome
• Reduces prescriber friction: they write one Rx, one reimbursement, one outcome metric

Competitor parallel: Sunbit (addiction DTx) uses telehealth + app bundling. Twill integrates DTx with nurse coaching.

5. New Comparison: Headspace Health (Gery + Gabby) vs. Pear

6. Proof of Economics: Cost Savings in Claims Data

Pear needs health economics evidence:

• Track claims 12 months pre- and post-reSET initiation for N=500+ patients
• Calculate: ER visits, hospitalizations, medication fills, quality-adjusted days
• Target: $2,500–$4,000 annual savings per patient (Welldoc benchmark = $3,252)
• Package for payer formulary inclusion (Evernorth model)

7. One NEW Competitive Angle: Partner with Telehealth Addiction Platform (e.g., Twin Health, Ro Prescription Care)

Twin Health (obesity DTx + telehealth) achieves 60%+ engagement via embedded clinical teams. Ro (telehealth + medication + app) hits 100K+ patients by making prescribing frictionless. Pear could:

• OEM reSET-O inside existing telehealth SUD platforms (Workit, SBIRT networks)
• Revenue share instead of licensing: Pear gets $50/patient/month if telehealth provider uses reSET-O in their workflow
• Zero direct payer negotiation; telehealth platform handles reimbursement
• Outcome: reSET-O becomes clinical standard inside telehealth, not a standalone Rx

FAQ

Why did Pear Therapeutics' SPAC business collapse? Pear's 2021–2022 playbook treated digital therapeutics like a pharma drug, achieving FDA clearance for reSET (2017), reSET-O (2018), and Somryst (2020) but ignoring that payers, not prescribers, control reimbursement. By 2021 Pear hit $110M in annual expenses against only $4.2M in revenue, with revenue concentrated around three payers on misaligned contracts.

CEO Corey McCann admitted on record that "commercial payers are laggards" who "can and will deny care."

What billing friction blocked DTx adoption? The buy-and-bill model—where a provider pays upfront, submits a claim, and waits for reimbursement—is described as "not common practice" for mental health clinicians. Therapists, counselors, and addiction specialists expect insurance to handle payment and won't float $500 per patient waiting 45 days.

This is why the 2026 fix routes billing through PBM infrastructure instead of provider manual claims.

How does the Big Health/CVS model fix distribution? Big Health embedded with CVS Pharmacy's PBM so DTx is billed at the pharmacy counter like a drug, with compliance tracked in the PBM data backbone and reimbursement triggered automatically by claim adjudication. The fix has Pear partner with CVS Health or another major PBM so the patient gets a prescription card or digital code at the counter with zero provider upfront cost.

Big Health's model is "payers first, prescribers second."

Why narrow Pear to a single indication? Pear ran reSET, reSET-O, and Somryst simultaneously—three different markets with three times the sales friction. The 2026 restart picks one, probably reSET for substance use disorder, because addiction treatment is underfunded, has high provider demand, and aligns with telehealth and DSA expansion.

The plan also signs UnitedHealth, Cigna, and Anthem to outcomes-based pilot reimbursement agreements before running prescriber sales.

How did competitors solve what Pear couldn't? Welldoc's BlueStar used direct-to-employer and health-plan contracts and proved $3,252 per patient in annual claims savings with value-based pricing. Big Health used CVS PBM integration, and Headspace Health (Ginger) moved to an employer-facing subscription with clinical delivery rather than prescription-only.

Click Therapeutics ended up acquiring Pear's reSET/reSET-O IP out of the bankruptcy auction.

Bottom Line

Pear's collapse was a distribution and credibility failure, not a clinical one. reSET and reSET-O work; FDA proved it. The problem was trying to commercialize DTx like a pharma drug (prescriber → patient) when payers control access (payer → provider → patient). A 2026 Pear turnaround requires:

1. One indication, one team, one story
2. Payer partnerships locked before launch (risk-sharing, value-based pricing)
3. PBM distribution (pharmacy-counter simplicity, zero provider friction)
4. Clinical bundling (DTx + telehealth, not DTx alone)
5. Economics proof ($3K+/patient savings, claims-backed)

Without these moves, reSET becomes a commodity bought by 1–2 payers and ignored by the rest. With them, reSET becomes embedded infrastructure—Pear's path to $100M+ ARR by 2028.